COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy
- PMID: 34854413
- PMCID: PMC8641750
- DOI: 10.4103/ijp.ijp_406_21
COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy
Conflict of interest statement
None
References
-
- Kontoyiannis DP, Lewis RE. Invasive zygomycosis: Update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20:581–607. - PubMed
-
- Ashourpour M, Djalali M, Djazayery A, Eshraghian MR, Taghdir M, Saedisomeolia A. Relationship between serum ferritin and inflammatory biomarkers with insulin resistance in a Persian population with Type 2 diabetes and healthy people. Int J Food Sci Nutr. 2010;61:316–23. - PubMed
-
- Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45:667–71. - PubMed
-
- Gangadharan D, Sivaramakrishnan S, Pandey A, Madhavan Nampoothiri K. Folate-producing lactic acid bacteria from cow's milk with probiotic characteristics. Int J Dairy Technol. 2010;63:339–48.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical